Pricing Log in Create free account

Nurix Therapeutics, Inc. (NRIX) vs Sarepta Therapeutics, Inc. (SRPT)

Nurix Therapeutics, Inc. and Sarepta Therapeutics, Inc. are both Biotechnology companies. Nurix Therapeutics, Inc. and Sarepta Therapeutics, Inc. are of similar size ($1.7B and $1.7B). Nurix Therapeutics, Inc. trades at the lower P/E: 6.2× against 182×. Nurix Therapeutics, Inc. grew revenue faster over the last twelve months: 738.8% against −19.0%. Nurix Therapeutics, Inc. has the higher net margin (42.0% vs 0.75%) and the higher return on invested capital (0.00% vs −2.26%). Across the 20 metrics below, Nurix Therapeutics, Inc. leads on 16 and Sarepta Therapeutics, Inc. on 4.

Valuation

Metric NRIX SRPT Biotechnology median
P/E 6.18 182.33 11.36
P/S 2.47 0.87 9.12
P/B 1.79 1.12 2.14
Price to free cash flow 4.68 9.91 26.34
EV/EBITDA 2.31 n/m 0.62
EV/Sales 0.97 0.83 8.56
Earnings yield 16.18% 0.55% (34.18%)
Free cash flow yield 21.37% 10.09% (23.62%)

Profitability

Metric NRIX SRPT Biotechnology median
Gross margin 100.00% 56.79% 67.24%
Operating margin 41.27% (2.50%) 0.00%
Net margin 42.01% 0.75% 0.00%
Free cash flow margin 52.68% 8.79% 0.00%
Return on equity 43.99% 1.04% (50.28%)
Return on assets 34.33% 0.44% (45.89%)
Return on invested capital 0.00% (2.26%) 0.00%

Growth

Metric NRIX SRPT Biotechnology median
Revenue growth (TTM) 738.76% (18.95%) 6.96%
EPS growth (last fiscal year) (5.90%) (404.70%) 29.86%
Revenue growth, 5-year CAGR 36.35% 32.41% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NRIX SRPT Biotechnology median
Debt to equity 0.00 0.46 0.00
Current ratio 8.44 3.46 4.72
Net debt to EBITDA 2.14 0.17 1.01

Dividend

Metric NRIX SRPT Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric NRIX SRPT Biotechnology median
Market cap 1.70b 1.72b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack